apoAsset: Change in management
12 February 2024
A change in management is pending at Apo Asset Management GmbH (apoAsset), the fund subsidiary of the Deutsche Apotheker- und Ärztebank (apoBank) and the Deutsche Ärzteversicherung (DÄV).
Mirko Engels (49), Head of Institutional Investors at apoBank, will join the management of the fund company on March 1, 2024, subject to the approval of the Federal Financial Supervisory Authority (BaFin) and the Bundesbank. Engels succeeds Claus Sendelbach (62), who is leaving the company after 13 years as part of a generational change. The other managing director of apoAsset for five years has been Dr. Heiko Victim.
Engels came to apoBank in 1999 and has been responsible for the institutional investment business for many years. He and his team at the bank continue to be responsible for looking after these customers. “We are pleased to have gained Mirko Engels, a proven investment expert with many years of experience in sales, for the management,” says Matthias Schellenberg, CEO of apoBank and also Chairman of the Supervisory Board of apoAsset. “His experience with commitment-oriented investors also enables us to have a stronger presence of apoAsset’s product portfolio in the bank’s institutional sales.”
Schellenberg thanked Sendelbach for his successful work for apoAsset for over 13 years. “Under Claus Sendelbach, apoAsset has developed into one of the most important providers of healthcare investments in Germany. This expertise is an important added value for us as a health bank, which we want to consistently exploit in the future. On behalf of the entire Supervisory Board, I wish Claus Sendelbach all the best for his future plans.”
Source: Apo Asset Management
